Compare Danaos Corporation (DAC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs TransMedics Group Inc — how do they compare? Danaos Corporation trades at $169.89 (market cap $3.10B), while TransMedics Group Inc trades at $77.31 (market cap $2.74B). The key difference: Danaos Corporation and TransMedics Group Inc are close in size by market cap, and Danaos Corporation pays a 2.35% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaos Corporation for 25 Days and TransMedics Group Inc for 24 Days on average.
| DAC | TMDX | |
|---|---|---|
Market Cap | $3.10B | $2.74B |
Volume | 286,008 | 949,331 |
Sector | Industrials | Health |
52-Week High | $170.22 | $150.42 |
52-Week Low | $84.05 | $61.99 |
Typical Hold Time | 25 Days | 24 Days |
Enterprise Value | $3.08B | $3.13B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaos Corporation (DAC) trades at $164.48, down 0.88% on the day, with strong fundamental metrics including a low P/E of 5.57 and robust profitability margins. The stock shows a bullish technical trend, trading above key moving averages, with recent earnings consistently beating expectations. The company maintains strong cash flow generation and has declared multiple dividends, reflecting financial health and shareholder returns.
The outlook remains positive given DAC's undervaluation, earnings momentum, and dividend payments. Key risks include shipping industry cyclicality and global trade volatility. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism amid strong fundamentals and technical strength.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
